DK0837672T3 - Præparationer og fremgangsmåder til behandling af T-cellemedierede sygdomme - Google Patents

Præparationer og fremgangsmåder til behandling af T-cellemedierede sygdomme

Info

Publication number: DK0837672T3
Authority: DK; Denmark
Prior art keywords: cell; mediated diseases; preparations; treating; methods
Prior art date: 1995-07-05

Application number

DK96924371T

Other languages

Danish (da)

English (en)

Inventor

Dana Elias

Irun R Cohen

Meir Shinitzky

Original Assignee

Yeda Res & Dev

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-07-05

Filing date

1996-07-02

Publication date

2004-03-22

1996-07-02 Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev

2004-03-22 Application granted granted Critical

2004-03-22 Publication of DK0837672T3 publication Critical patent/DK0837672T3/da

Links

210000001744 T-lymphocyte Anatomy 0.000 title abstract 4
201000010099 disease Diseases 0.000 title abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
230000001404 mediated effect Effects 0.000 title abstract 3
238000000034 method Methods 0.000 title 1
238000002360 preparation method Methods 0.000 title 1
208000023275 Autoimmune disease Diseases 0.000 abstract 1
108090000695 Cytokines Proteins 0.000 abstract 1
102000004127 Cytokines Human genes 0.000 abstract 1
239000000427 antigen Substances 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
239000000839 emulsion Substances 0.000 abstract 1
230000002757 inflammatory effect Effects 0.000 abstract 1
229940028435 intralipid Drugs 0.000 abstract 1
239000002960 lipid emulsion Substances 0.000 abstract 1
230000008506 pathogenesis Effects 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Molecular Biology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Rehabilitation Therapy (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Marine Sciences & Fisheries (AREA)

DK96924371T 1995-07-05 1996-07-02 Præparationer og fremgangsmåder til behandling af T-cellemedierede sygdomme DK0837672T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IL11445895A IL114458A0 (en)	1995-07-05	1995-07-05	Therapeutic preparations for treatment of T cell mediated diseases
PCT/US1996/011373 WO1997002016A1 (fr)	1995-07-05	1996-07-02	Preparations et procedes de traitments de maladies mediees par les lymphocytes t

Publications (1)

Publication Number	Publication Date
DK0837672T3 true DK0837672T3 (da)	2004-03-22

Family

ID=11067727

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK96924371T DK0837672T3 (da)	1995-07-05	1996-07-02	Præparationer og fremgangsmåder til behandling af T-cellemedierede sygdomme

Country Status (22)

Country	Link
EP (1)	EP0837672B9 (fr)
JP (2)	JP4357595B2 (fr)
KR (1)	KR100435040B1 (fr)
CN (1)	CN1102382C (fr)
AT (1)	ATE254451T1 (fr)
AU (1)	AU714970B2 (fr)
CA (1)	CA2226013C (fr)
CZ (1)	CZ298A3 (fr)
DE (1)	DE69630787T2 (fr)
DK (1)	DK0837672T3 (fr)
ES (1)	ES2211963T3 (fr)
HR (1)	HRP960315A2 (fr)
HU (1)	HU223081B1 (fr)
IL (2)	IL114458A0 (fr)
MX (1)	MX9800190A (fr)
NO (1)	NO320363B1 (fr)
PT (1)	PT837672E (fr)
SI (1)	SI0837672T1 (fr)
UY (1)	UY24275A1 (fr)
WO (1)	WO1997002016A1 (fr)
YU (1)	YU40796A (fr)
ZA (1)	ZA965666B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5993803A (en) *	1996-08-30	1999-11-30	Yeda Research And Development Co., Ltd.	Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
US6022697A (en)	1996-11-29	2000-02-08	The Regents Of The University Of California	Methods for the diagnosis and treatment of insulin-dependent diabetes mellitus
US7572631B2 (en)	2000-02-24	2009-08-11	Invitrogen Corporation	Activation and expansion of T cells
US7541184B2 (en)	2000-02-24	2009-06-02	Invitrogen Corporation	Activation and expansion of cells
IL142536A0 (en) *	2001-04-11	2002-03-10	Yeda Res & Dev	Carriers for therapeutic preparations for treatment of t-cell mediated diseases
WO2003096967A2 (fr)	2002-05-21	2003-11-27	Yeda Research And Development Co. Ltd.	Vaccins d'adn codant des proteines de choc thermique
US20050084967A1 (en)	2002-06-28	2005-04-21	Xcyte Therapies, Inc.	Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
WO2004098489A2 (fr) *	2003-05-12	2004-11-18	Peptor Ltd.	Compositions et procedes de modulation d'epitopes de hsp60 specifiques
WO2005048914A2 (fr) *	2003-11-24	2005-06-02	Yeda Research & Development Co. Ltd.	Vaccins d'adn codant pour des fragments de peptide hsp60 permettant de traiter les maladies auto-immunes
EP1835933A4 (fr)	2005-01-04	2015-01-07	Yeda Res & Dev	Hsp60, peptides hsp60 et vaccins a base de lymphocytes t pour immunomodulation
EP1945246A4 (fr)	2005-09-22	2009-03-11	Irun R Cohen	Fragments immunogènes de domaines constants du récepteur de lymphocytes t et peptides dérivés de ceux-ci
JP2019523633A (ja) *	2016-04-29	2019-08-29	アライムファーマシューティカルズ，インコーポレーテッド	組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4395394A (en) *	1979-10-26	1983-07-26	Pfizer Inc.	Use of lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
IL63734A (en) *	1981-09-04	1985-07-31	Yeda Res & Dev	Lipid fraction,its preparation and pharmaceutical compositions containing same
SE8405493D0 (sv) *	1984-11-01	1984-11-01	Bror Morein	Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5114844A (en) *	1989-03-14	1992-05-19	Yeda Research And Development Co., Ltd.	Diagnosis and treatment of insulin dependent diabetes mellitus
IL97709A (en) *	1990-03-30	2005-05-17	Brigham & Womens Hospital	Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis

1995
- 1995-07-05 IL IL11445895A patent/IL114458A0/xx unknown
1996
- 1996-07-02 IL IL12275596A patent/IL122755A/en not_active IP Right Cessation
- 1996-07-02 CZ CZ982A patent/CZ298A3/cs unknown
- 1996-07-02 ES ES96924371T patent/ES2211963T3/es not_active Expired - Lifetime
- 1996-07-02 DK DK96924371T patent/DK0837672T3/da active
- 1996-07-02 MX MX9800190A patent/MX9800190A/es unknown
- 1996-07-02 KR KR10-1998-0700036A patent/KR100435040B1/ko not_active Expired - Fee Related
- 1996-07-02 SI SI9630662T patent/SI0837672T1/xx unknown
- 1996-07-02 DE DE69630787T patent/DE69630787T2/de not_active Expired - Lifetime
- 1996-07-02 CA CA2226013A patent/CA2226013C/fr not_active Expired - Lifetime
- 1996-07-02 CN CN96196402A patent/CN1102382C/zh not_active Expired - Lifetime
- 1996-07-02 JP JP50531797A patent/JP4357595B2/ja not_active Expired - Lifetime
- 1996-07-02 HU HU9802834A patent/HU223081B1/hu active IP Right Grant
- 1996-07-02 AU AU64844/96A patent/AU714970B2/en not_active Expired
- 1996-07-02 PT PT96924371T patent/PT837672E/pt unknown
- 1996-07-02 AT AT96924371T patent/ATE254451T1/de active
- 1996-07-02 WO PCT/US1996/011373 patent/WO1997002016A1/fr not_active Ceased
- 1996-07-02 EP EP96924371A patent/EP0837672B9/fr not_active Expired - Lifetime
- 1996-07-04 ZA ZA965666A patent/ZA965666B/xx unknown
- 1996-07-04 HR HR114458A patent/HRP960315A2/hr not_active Application Discontinuation
- 1996-07-05 UY UY24275A patent/UY24275A1/es unknown
- 1996-07-05 YU YU40796A patent/YU40796A/sh unknown
1998
- 1998-01-02 NO NO19980013A patent/NO320363B1/no not_active IP Right Cessation
2009
- 2009-06-15 JP JP2009141914A patent/JP2009242412A/ja active Pending

Also Published As

Publication number	Publication date
SI0837672T1 (en)	2004-04-30
HU223081B1 (hu)	2004-03-29
PT837672E (pt)	2004-03-31
DE69630787T2 (de)	2004-10-07
UY24275A1 (es)	2000-12-29
CZ298A3 (cs)	1998-06-17
AU6484496A (en)	1997-02-05
JP4357595B2 (ja)	2009-11-04
YU40796A (sh)	1998-11-05
ATE254451T1 (de)	2003-12-15
IL122755A0 (en)	1998-08-16
JP2009242412A (ja)	2009-10-22
MX9800190A (es)	1998-04-30
ES2211963T3 (es)	2004-07-16
EP0837672A4 (fr)	1999-01-27
NO980013D0 (no)	1998-01-02
CN1102382C (zh)	2003-03-05
DE69630787D1 (de)	2003-12-24
IL122755A (en)	2004-07-25
HRP960315A2 (en)	1998-02-28
JPH11508899A (ja)	1999-08-03
CA2226013C (fr)	2012-09-18
HUP9802834A2 (hu)	1999-03-29
EP0837672A1 (fr)	1998-04-29
NO320363B1 (no)	2005-11-28
EP0837672B9 (fr)	2005-06-15
ZA965666B (en)	1997-01-27
NO980013L (no)	1998-02-19
AU714970B2 (en)	2000-01-13
EP0837672B1 (fr)	2003-11-19
CN1193907A (zh)	1998-09-23
WO1997002016A1 (fr)	1997-01-23
CA2226013A1 (fr)	1997-01-23
HUP9802834A3 (en)	2001-08-28
KR19990028738A (ko)	1999-04-15
KR100435040B1 (ko)	2004-08-18
IL114458A0 (en)	1995-11-27

Publication	Publication Date	Title
ES2152483T3 (es)	2001-02-01	Aplicacion terapeutica en anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de celulas b.
DK0837672T3 (da)	2004-03-22	Præparationer og fremgangsmåder til behandling af T-cellemedierede sygdomme
ES2179077T3 (es)	2003-01-16	Acido glutamico decarboxilasa clonada.
DK0914144T3 (da)	2001-04-09	Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
EP0751781A4 (fr)	1999-09-22	Procede de prevention ou de traitement de maladies caracterisees par des cellules neoplasiques exprimant le cd40
DK442688A (da)	1988-10-07	Fremgangsmaade og praeparat til behandling af non-ige-medierede lidelser
ES2190434T3 (es)	2003-08-01	Anticuerpos recombinantes especificos para tnf-alfa.
ES2530769T3 (es)	2015-03-05	Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno
DK0920322T3 (da)	2003-08-04	Anvendelser af modificeret autologt blod til behandling af autoimmunitetssygdomme
ES2164914T3 (es)	2002-03-01	Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
DE69719754D1 (de)	2003-04-17	Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
ES2074268T3 (es)	1995-09-01	Vacunacion idiotipica contra el linfoma de celulas b.
Bonnefoy et al.	2011	TGF-β–exposed plasmacytoid dendritic cells participate in TH17 commitment
DE69738692D1 (de)	2008-06-26	LO-CD2a ANTIKÖRPER UND DESSEN VERWENDUNGEN ZUR HEM
DK0687300T3 (da)	2001-12-31	LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation
Ito et al.	2020	CCR5 is a novel target for the treatment of experimental alopecia areata
DE60112768D1 (de)	2005-09-22	Behandlung von entzündlichen erkrankungen
DE69928523D1 (de)	2005-12-29	Verotoxin b untereinheit zur immunisierunug
DK0959899T3 (da)	2009-09-07	LO-CD2a-antistof samt dets anvendelse til h mning af T-celleaktivering og -proliferation
HUP9901077A2 (hu)	1999-07-28	Gyógyszerkészítmény T-sejtek által közvetített gyulladásos bőrbetegségek ellen
SU644924A1 (ru)	1979-01-30	Армоопалубочный пакет
Maurer	1989	Regulation of the antigen-presentation capacity of human dermal fibroblasts by gamma-interferon.
UA28518A (uk)	2000-10-16	Спосіб визначення алергену у хворих на лікарську хворобу
MX9800821A (es)	1998-10-31	Aislamiento y/o conservacion de celulas dentriticas para la inmunoterapia del cancer de la prostata.
HN1996000030A (es)	1997-06-14	Uso de una mezcla itraconazol-secnidazol para el tratamientode enfermedades infecciosas en el aparato reproductor femenino.